News

Banana Boat gears up for summer with launch of new products

BY Antoinette Alexander

SHELTON, Conn. — Energizer Personal Care, the makers of Banana Boat brand sunscreen, announced the availability of four new products in mass grocery and drug retailers nationwide, including a formula designed specifically for men.

"Banana Boat is the brand that provides trusted protection and offers a product for everyone, which is further shown through our creation of a sunscreen line specifically for men, as well as the only alcohol-free, tear-free, sting-free kids clear spray," said Carla Luca, senior brand manager of Banana Boat brand sunscreens. "Each new innovation offers multi-skin benefits that go beyond UVA/UVB protection, which is important to today’s shopper. For example, our Triple Defense Sunscreen for Men Lotion and Clear UltraMist combat odor while hydrating the skin with a contemporary masculine scent, so men can be confident in their sunscreen choice. Banana Boat is proud to offer a portfolio of sun care products that meets the needs of our dynamic consumers."

The Banana Boat Triple Defense Sunscreen for Men is the first Banana Boat sunscreen portfolio designed specifically for men, created following a 2012 survey by The Skin Cancer Foundation, which revealed that men older than age 50 years are more than twice as likely as women to develop skin cancer, yet only 51% of men in the United States admitted to using sunscreen in the past 12 months. Men also were found to be less knowledgeable than women about the proper methods to protect themselves against sun exposure and skin cancer.

Banana Boat Triple Defense Sunscreen for Men contains ActiveProtect Technology and provides heavy-duty broad spectrum UVA/UVB protection, which kicks in and stays strong when the sun’s rays are most intense. The lightweight formula combats odor, even while sweating, and hydrates the skin. Banana Boat Triple Defense Sunscreen for Men Lotion and Clear UltraMist is available in SPF 30 and 50+.

The Banana Boat Kids Free Clear UltraMist Sunscreen’s is the only alcohol-free, tear-free, sting-free kids clear spray, the company stated. The formulation is pediatrician-tested and goes on clear to provide fast and even coverage. Banana Boat Kids Free Clear UltraMist Sunscreen is available in SPF 50+.

Banana Boat Sport Performance Clear UltraMist Sunscreen with Powerstay Technology was designed for the sport enthusiast and active individual who doesn’t want to be slowed down while out in the sun. Powerstay Technology is the brand’s latest innovation, which helps sunscreen stay on strong throughout all outdoor activities. This new formula has been designed to provide better application aesthetics, including a lightweight feel compared to the original formula. Banana Boat Sport Performance Clear UltraMist Sunscreen with Powerstay Technology is available in SPF 15, 30, 50+ and 100.

Building on the Protect & Hydrate Sunscreen Lotion introduced last year, Protect & Hydrate Sunscreen Clear UltraMist provides a 2-in-1 combination of sunscreen and all-day moisturizer, combining aloe with vitamins C and E. Banana Boat Protect & Hydrate Sunscreen Clear UltraMist is available in SPF 30 and 50+.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Armada Health Care convenes 10th Annual Specialty Pharmacy Summit & Expo

BY Michael Johnsen

LAS VEGAS — A panel of speakers from all facets of health care convened yesterday to discuss the growth of the specialty pharmaceuticals industry during the 10th Annual Specialty Pharmacy Summit & Expo, hosted by Armada Health Care. The four-day conference brought together more than 3,000 stakeholders from the specialty pharmacy industry.

The presentations focused on the notion that the pharmaceutical industry is shifting to meet the high medical need of specialty patients, and that patients are facing new challenges as a result of the impact of the Affordable Care Act, particularly as it relates to specialty drug coverage.

The evolving regulatory landscape, the shift to high deductible plans and increasing healthcare consolidation in the industry will likely change the patient and caregiver experience, the speakers noted. Cost inflation on drugs will continue to be a problem, and longer patient lifespans will further exacerbate the cost management challenge. However, through management of the "whole patient" and identification of new ways to focus on cost, quality and access, providers can continue to deliver the care coordination necessary to produce favorable patient outcomes.

Speakers who participated in the general session discussion included Lawrence Irene, CEO, Armada Health Care; Randy Falkenrath, SVP specialty pharmacy services, CVS Caremark; Jim Robinson, president, Astellas Pharma US; Myrtle Potter, CEO Myrtle Potter & Company and Myrtle Potter Media; and Michael J. Fox, award-winning actor, author, comedian, producer and patient advocate.

The morning concluded with a presentation by Fox, who told the audience of his personal struggles following his Parkinson’s disease diagnosis in 1991. While he had considered himself an eternal optimist, Fox admitted that during a particularly low point in his life, he lamented to his wife that he "would never finish [his] book on optimism." He spoke of the enduring support from his family and the steps he took to overcome the obstacles related to his disease. 

 

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Bayer/Merck combined portfolio represents leading position across significant OTC categories

BY Michael Johnsen

Bayer agreed to acquire the consumer care business of U.S. pharmaceutical company Merck for a purchase price of $14.2 billion. The OTC acquisition will give Bayer the global No. 2 position in nonprescription products following recently announced consolidations in this growing healthcare industry segment, and will significantly enhance Bayer’s business across multiple therapeutic categories and geographies. Merck’s consumer care business includes such leading brands as Claritin, Coppertone and Dr. Scholl’s. Pro forma sales of the combined businesses in 2013 amounted to $7.4 billion with Merck’s business, contributing approximately $2.2 billion. 

Upon completion of the acquisition, Bayer is expected to achieve global leadership positions in dermatology and gastrointestinals, and advance to the No. 2 position in the cold, allergy, sinus and flu category. Bayer will remain No. 2 in nutritionals and No. 3 in analgesics. Overall, the proposed GlaxoSmithKline-Novartis combination represents the largest consumer health business with about 5.7% share, according to reports. The Bayer/Merck combination comes in second with around 4.5% share. McNeil Consumer rounds out the top-three globally with a share just above 4%.  

But the combined heft a Bayer/Merck combination will wield may carry a little greater weight in the U.S. OTC market. 

There is no overlap between the OTC product portfolios of Bayer and Merck, and they hold a leading vendor position in 14 categories collectively. Bayer is the No. 1 or No. 2 vendor in seven categories — lice treatments (RID), antacid/analgesic (Alka Seltzer), feminine pain relievers (Midol), internal analgesic tablets (Aleve/Bayer), stomach remedy liquid/powder (Phillips), multivitamins (One-A-Day) and cold sore medication (Campho Phenique). Meanwhile, Merck also is the No. 1 or No. 2 vendor in seven categories — wart removers (Dr. Scholl’s Freeze Away), nasal spray (Afrin), cold/allergy/sinus tablets (Claritin), laxative/stimulant liquid/powder/oil (MiraLax), athlete’s foot medication (Tinactin/Lotrimin AF), foot care and foot care devices (both Dr. Scholl’s). 

In 10 of the above categories, the new Bayer/Merck combination possess at least a 20% market share (rounding up) — antacid/analgesic (81%), foot care devices (54.6%), feminine pain relievers (45.2%), athlete’s foot medication (42.5%), lice treatments (33.4%), laxative/stimulant liquid/powder/oil (29.5%), wart removers (28%), stomach remedy liquid/powder (22.1%), multivitamins (20.2%) and internal analgesic tablets (19.8%). (Marketshare data courtesy IRI for the 52 weeks ended Dec. 29, 2013 across total U.S. multi-outlets.)

The Bayer/Merck combination may further boost its hold on the allergy market if the Food and Drug Administration approves Merck’s recent switch application for Singulair. However, that may become a separate deal as, according to reports, Merck has retained the switch rights to all of the prescription medicines in its portfolio. 

The question as to whether a Singulair switch will even happen has been placed into some doubt — the FDA’s advisory committee recently recommended against the switch out of concern that people would attempt to self-diagnose a more serious asthma condition. However, there is precedent for both the FDA switching a remedy against the advice of its advisory committee — in fact, it is Merck’s Oxytrol for Women for the new-to-OTC category of overactive bladder that bears that distinction — and a product carrying a dual indication for both OTC and prescription-only for a more serious indication — when Procter & Gamble’s Prilosec OTC was switched it was indicated to treat frequent heartburn; the same strength of omeprazole is available as a prescription remedy for the more serious condition GERD.

keyboard_arrow_downCOMMENTS

Leave a Reply

admin says:
Jun-10-2014 03:39 pm

this is an interesting article

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?